SOLIRIS (eculizumab): The first treatment specifically approved for PNH

For US Healthcare Professionals

Sign Up

Learn more about SOLIRIS

Join the growing network of physicians interested in new treatments and ways to deliver the best possible care for patients with PNH. Sign up to receive regular updates on SOLIRIS® (eculizumab) therapy and timely PNH news and information.

* indicates required field
Last Name:*  
First Name:*  
Address:*  
Address2:  
City:*  
State:*  
Zip Code:*  
At this time, SOLIRIS is commercially available only in the U.S.
Phone Number:*  
Email:*  
Confirm Email:*  
 
Have you ever treated a PNH patient?   Yes
 
How many patients are you currently treating?*  
  I would like to enroll a patient in the PNH Registry
  I would like someone from Alexion to contact me
  I would like to order support materials for my office
  PNH Disease Materials — Information about healthy living with PNH, screening for the disease, and diagnosis
  SOLIRIS Patient Materials — Resources for your patients, including Brochures, Educational Materials, and Financial Assistance
OneSource™ Materials — Information for your PNH patients about the SOLIRIS OneSource Treatment Support Program, providing ongoing personalized treatment support and access to therapy
 
  I'm interested in receiving ongoing information about SOLIRIS therapy and regular updates on advances in PNH research and management.*

Please review our Terms and Conditions in addition to our Privacy Policy. By submitting your registration, you are agreeing to the terms of use and our Privacy Policy.
 
 

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.